Stocks · News reference

Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5

Jun 11, 2026, 9:44 AMBenzinga Newsdesk

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14 to $14.5.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jun 11, 2026, 9:44 AM
Checked: Jun 11, 2026, 9:44 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaJun 25, 2026, 8:40 PMBenzinga Newsdesk
Aytu BioPharma And And Lannett Terminate Metadate Agreement Effective June 23, 2026; Co. To Continue Selling Existing Metadate Inventory And Pay Royalties Until Sales Cease
AYTU
SEC EDGARJun 25, 2026, 8:31 PMSEC EDGAR
8-K filing — AYTU BIOPHARMA, INC (AYTU)
Filed: 2026-06-25 AccNo: 0001437749-26-021707 Size: 181 KB Item 1.02: Termination of a Material Definitive Agreement
AYTU